OABINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABIW
OmniAb, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.69+0.10 (+2.18%)
Close on Oct 19, 2026
- Market cap
- $604.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2007 to 2025
Operating margin
-369.5%
Net margin
-347.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -29.3% | -31.9% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2007 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -23.4% | |
| Return on assets | – | – | -20.7% | |
| Current ratio | – | – | 4.02 | |
| Capex to revenue | – | – | 3.0% | |
| Diluted shares | – | – | 114M |
Where the cash went
Fiscal 2021 to 2025, five years combined
OmniAb generated $87.73M from operations and spent $25.32M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$87.73M
Used
$25.32M
Capital expenditure$25.32M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-347.0%
×Asset turnover0.06×
×Equity multiplier1.13×
=Return on equity, FY2025-23.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -347.0% | 0.06× | 1.13× | -23.4% |
| FY2024 | -235.1% | 0.08× | 1.16× | -20.6% |
| FY2023 | -148.2% | 0.09× | 1.21× | -15.4% |
| FY2022 | -37.8% | 0.16× | 1.26× | -7.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$64.78M
- Cash generatingOperating cash flow above zero-$36.46M
- Return on assets improvedROA up on the prior year-16.5% → -19.9%
- Earnings backed by cashOperating cash flow above net income-$36.46M vs -$64.78M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.52 → 4.02
- No dilutionShare count did not rise102M → 114M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.07 → 0.06